Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice

BACKGROUND: There is substantial evidence that patients with ankylosing spondylitis (AS) have high response rates to tumour necrosis factor inhibitors (TNFi), a low likelihood of successful treatment termination, but yet a limited drug retention. Whereas several reports have assessed drug retention...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindström, Ulf, Olofsson, Tor, Wedrén, Sara, Qirjazo, Ilia, Askling, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540538/
https://www.ncbi.nlm.nih.gov/pubmed/31138285
http://dx.doi.org/10.1186/s13075-019-1908-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540538/
https://www.ncbi.nlm.nih.gov/pubmed/31138285
http://dx.doi.org/10.1186/s13075-019-1908-9

Ejemplares similares